| Literature DB >> 30200407 |
Mohamed-Elamir F Hegazy1,2, Ahmed R Hamed3,4, Mahmoud A A Ibrahim5, Zienab Talat6, Eman H Reda7, Nahla S Abdel-Azim8, Faiza M Hammouda9, Seikou Nakamura10, Hisashi Matsuda11, Eman G Haggag12, Paul W Paré13, Thomas Efferth14.
Abstract
Euphorbia species are rich in diterpenes. A solvent extraction of Euphorbia sanctae-catharinae, a species indigenous to the Southern Sinai of Egypt, afforded several premyrsinane diterpenoids (1⁻4) as well as previously reported metabolites (5⁻13) that included three flavonoids. Isolated compounds were chemically characterized by spectroscopic analysis. Identified compounds were bioassayed for anti-proliferative activity in vitro against colon (Caco-2) and lung (A549) tumor cell lines. Compound 9 exhibited robust anti-proliferative activity against A549 cells (IC50 = 3.3 µM). Absolute configurations for 8 versus 9 were determined by experimental and TDDFT-calculated electronic circular dichorism (ECD) spectra.Entities:
Keywords: Euphorbia sanctae-catharinae; Euphorbiaceae; TDDTF-ECD; diterpenes; flavonoids; tumor anti-proliferative activity
Mesh:
Substances:
Year: 2018 PMID: 30200407 PMCID: PMC6225227 DOI: 10.3390/molecules23092221
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Identified compounds from Euphorbia sanctae-catharinae. Ac = acetyl, Bz = benzoyl, Nic = nicotinoyl, Bu = butanoyl, iBu = isobutanoyl, 2MeBu = 2-methylbutanoyl, 2MeBu 3-dimethylbutanoyl, Nic = nicotinoyl.
1H-NMR and 13C-NMR spectral data of compounds 1–5 (600 MHz, δ-ppm).
| No. | 1 | 2 | 3 | 4 | ||||
|---|---|---|---|---|---|---|---|---|
| δC | δC | δC | δC | |||||
| 1α | 3.12 dd (8.4, 13.8) | 42.9 | 3.14 dd (8.4, 13.8) | 42.9 | 3.15 dd (7.2, 13.8) | 42.9 | 3.14 dd (7.8, 13.2) | 42.9 |
| 1β | 1.59 dd (12.6, 13.2) | 1.60 dd (13.2) | 1.61 dd (13.8, 13.2) | 1.61 dd | ||||
| 2 | 1.80 m | 37.5 | 1.86 m | 37.5 | 1.87 m | 37.3 | 1.79 m | 37.5 |
| 3 | 5.24 dd (3.6, 6.0) | 78.4 | 5.23 t | 78.4 | 5.36 t (3.6) | 78.3 | 5.21 t | 77.3 |
| 4 | 2.32 m | 50.4 | 2.32 m | 50.5 | 2.34 m | 50.4 | 2.36 dd (3.0) | 50.6 |
| 5 | 6.18 d (11.4) | 68.8 | 6.21 d (12.0) | 69.1 | 6.46 d (11.4) | 69.9 | 6.23 d (12.0) | 69 |
| 6 | ---- | 47.4 | ---- | 47.8 | ---- | 48.2 | ---- | 47.7 |
| 7 | 4.48 d (6.6) | 70.7 | 4.72 d (6.6) | 71 | 4.97 d (6.6) | 70.7 | 4.85 d (12.6) | 70.8 |
| 8α | 2.09 m | 23.9 | 2.14 m | 21.4 | 2.05 m | 22.2 | 2.09 m | 23.9 |
| 8β | 1.80 brd (17.0) | 23.9 | 1.77 brd (17.0) | 21.4 | 1.87 brd (17.0) | 22.2 | 1.90 d (13.2) | 23.9 |
| 9 | 0.72 m | 18.9 | 0.77 m | 18.4 | 0.72 m | 19.1 | 0.62 m | 19 |
| 10 | ---- | 18.2 | ---- | 18.3 | ---- | 18.4 | ---- | 18.3 |
| 11 | 0.72 m | 21.4 | 0.77 m | 18.5 | 0.72 m | 21.5 | 0.62 m | 21.3 |
| 12 | 3.37 d (6) | 34.8 | 3.46 d (5.4) | 33.9 | 3.55 d (6.6) | 35.3 | 3.46 d (3.6) | 35 |
| 13 | ---- | 86.0 | ---- | 85.9 | ---- | 85.9 | ---- | 85.8 |
| 14 | ---- | 204.5 | ---- | 204.5 | ---- | 204.4 | ---- | 204.3 |
| 15-OH | 4.44 s | 84.1 | 4.44 s | 84.1 | 4.45 s | 84.2 | 4.48 s | 84.1 |
| 16 | 0.87 d (6.0) | 14.1 | 0.86 d (1.8) | 14.2 | 0.86 d (6.0) | 14 | 0.87 d (14.4) | 14.7 |
| 17α | 4.39 d (12.0) | 63.6 | 4.81 d (12.0) | 64 | 4.58 d (11.4) | 63.4 | 4.67 (d, | 64.5 |
| 17β | 4.31 d (12.0) | 4.46 d (12.0) | 4.91 d (10.8) | 4.46 brd (11.4) | ||||
| 18 | 1.04 s | 29.5 | 1.05 s | 29.5 | 1.06 s | 29.5 | 1.05 s | 29.5 |
| 19 | 0.90 s | 14.9 | 0.94 s | 14.9 | 0.95 s | 15 | 0.93 s | 14.9 |
| 20 | 1.68 s | 24.6 | 1.73 s | 24.6 | 1.66 s | 25 | 1.71 s | 25.8 |
1H-NMR of other signals (δ), for 1: O-Prop: 2.31 (q, J = 7.0 Hz), 1.08 (t, J = 7.0 Hz); O-3MeBu, 1.97 m, 2.32 m, 0. 90 (d, J = 7.8 Hz), 0.92 (d, J = 7.8 Hz); OAc-7, 2.08 (s); OAc-13, 2.09 (s); OAc-17, 2.06 (s). For 2: O-Prop: 2.30 (q, J = 8.4 Hz), 1.08 (t, J = 8.4 Hz); O-iBu, 2.39 m, 1.07 (d, J = 7.0 Hz), 1.09 (d, J = 7.0 Hz); OBz, 7.91 (AA′), 7.58 (C), 7.47; OAc-7, 2.14 (s); OAc-13, 2.15 (s). For 3: O-Prop: 1.08 (t, J = 7 Hz), 2.45 (q, J = 7 Hz); OBz, 7.70 (brd, J = 7.2 Hz), 7.52 (brdd, J = 7.2 Hz), 7.33 m, 7.11 (m), 7.00 (brt, J = 7.2); OAc-7, 2.12 (s); OAc-13, 2.17 (s). For 4: O-Prop: 1.08 (t, J = 7.8 Hz),2.25 (q, J = 9.0 Hz); O-MeBu, 2.14 m, 1.29 m, 1.06 (d, J = 7.8 Hz), 1.07 (t, J = 7.8 Hz); O-Nic, 7.43 (dd, J = 4.8, 7.8 Hz), 8.18 (t, J = 7.8 Hz), 8.80 (br d, J = 7.8 Hz), 9.14 br s; OAc-7, 2.10 (s); OAc-13, 2.05 (s). 13C-NMR other signals (δ), for 1: O-Prop: 8.9, 27.8; O-3MeBu, 21.4, 21.4, 26.5, 42.8; OAc-7, 170.0; OAc-13, 170.7; OAc-17, 170.4; C=O (prop, 174.2); C=O (3-MeBu, 174.3). For 2: O-Prop: 8.9, 27.7; O-iBu, 34.9, 18.6, 19.0; OBz, 128.9, 129.4, 133.6, 128.9, 129.4, 130.1; OAc-7, 170.0; OAc-13, 170.0; C=O (prop, 170.7); C=O (iBu, 174.1). For 3: O-Prop: 8.8,27.6; OBz-17, 132.9, 129.2, 127.9, 132.7, 127.9, 129.2, 129.4; OBz-5, 129.4, 129.2, 127.9, 129.6, 127.9, 129.2; OAc-7, 170.2; OAc-13, 170.2; C=O (prop, 170.8); C=O (OBz-5, 165.3); C=O (OBz-17, 173.6). For 5: O-Prop: 8.9, 27.8; O-MeBu, 11.6, 40.8, 14.9, 26.0; O-Nic, 153.9, 150.6, 136.9, 125.8, 123.7; OAc-7, 170.0; OAc-13, 170.7.
Figure 2Observed DQF-COSY and HMBC correlations for 1–4.
Figure 3Observed NOESY correlations for 1–4.
Figure 4Experimental and theoretical ECD spectra for compounds 8 (i) and 9 (ii).
Figure 5Concentration-response curve fits of the effect of isolated compounds 1–6 (A) and 7–13 (B) on the cell proliferation of Caco-2 (green triangles) or A549 (blue spheres). Cell proliferation was determined as % of vehicle control (MTT reduction assay) as detailed in the Experimental section.
IC50 values for 1–13 against proliferation of human Caco-2 and A549 tumor cell lines.
| Compound | IC50 on Caco-2 (µM) a | IC50 on A549 (µM) a |
|---|---|---|
|
| 75.8 (0.950) | >100 |
|
| 40.5 (0.989) | 48.5 (0.927) |
|
| 31.0 (0.999) | 21.5 (0.924) |
|
| 33.2 (0.993) | 32.8 (0.988) |
|
| 43.5 (0.999) | 50.1 (0.9960) |
|
| 33.3 (0.984) | 33.1 (0.983) |
|
| 40.3 (0.979) | 60.3 (0.937) |
|
| 26.1 (0.979) | 31.3 (0.971) |
|
| 29.4 (0.972) | 3.3 (0.996) |
|
| 43.9 (0.975) | >100 |
|
| 50.2 (0.993) | >100 |
|
| 44.7 (0.961) | >100 |
|
| 79.4 (0.843) | >100 |
| Doxorubicin HCl | 0.7 (0.999) | 0.4 (0.987) |
a Goodness of fit values (R2) given in parentheses based on non-linear regression using GraphPad prism V 6.0 software (GraphPad Software Inc., San Diego, CA, USA).
Figure 6Photomicrographic images of A549 cells depict increasing morphological toxicity include cell monolayer disruption and cell shrinkage with 48 h exposure to 9 at increasing concentrations. Magnification = 150×.